RECANTHIA

Breast cancer · France

Know, before treating,
who will respond to treatment.

In triple-negative breast cancer, a large share of patients do not fully respond to their treatment. Recanthia reads a signature of master regulators, the genes that orchestrate the tumour’s activity, to understand and predict that response: first for industry research, then, after validation, to support doctors.

The flyerContact us

The need

Breast cancer in France.

61,214

new cases in 2023 INCa

1 in 8

women affected during their lifetime Ameli

12,765

deaths in 2023 INCa

≈ 15%

of breast cancers are triple-negative, often in young women Institut Curie

The question: before treating, knowing which patients will respond to their treatment — and looking sooner for another option for the others.

Our approach

A signature read on the diagnostic biopsy.

  1. 1Biopsy

    The sample already taken at diagnosis.

  2. 2RNA

    The tumour’s active genes.

  3. 3Master regulators

    The conductors that drive those genes.

  4. 4Response

    Will respond, or will not, to treatment.

Our platform BRCA.cRegMap is developed by two CRCLille teams in Lille, France.

The offer

Research first, then the clinic.

From 2027 · Industry

Research services

For pharma, biotechs and CROs: response and resistance profiles to treatments, mechanisms, evaluation of candidate molecules.

By 2031–2032 · Clinic

Decision support

After clinical validation and approval: informing treatment choice, before treating. This is not a test available today.

Roadmap

  1. 2027

    Launch of research services.

  2. 2028

    Robustness: independent cohorts, reliability, limits.

  3. 2029–2030

    Clinical studies and regulatory preparation.

  4. 2031–2032

    Goal: clinical access.

Target timeline, conditional on results, partners and funding.

Team

Two co-founders, two CRCLille teams.

Maxime GremberCo-founder · CEOmaxime.grember@recanthia.com
Dr Nathan Horochowska LaneretCo-founder · CTOnathan.hl@recanthia.com

With scientific support from the Cell plasticity and cancer team and the Digital systems and computational cancer team.

Flyer and video

The key facts, to take away.

Download the flyer (PDF) ↓

Support us

Fund, collaborate, spread the word.

We are raising €1M for 2027–2028 to launch the research services and mature the technology. The company is being set up.

Save the contact